Phase 2 trial of BIO-11006 for acute respiratory distress syndrome (ARDS) who are recieving mechanical ventilation as standard of care.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs BIO-11006 (Primary)
- Indications Respiratory distress syndrome
- Focus Therapeutic Use
- Acronyms NCT03202395
- 07 Nov 2017 According to a BioMarck Pharmaceuticals media release, first patient has been dosed.
- 07 Nov 2017 New trial record